Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809933 | 1.00 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL16167492 | 0.91 | TRPV1 (0.67) | TRPV1 | |
| SCHEMBL6301671 | 0.91 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL7648757 | 0.89 | TRPV1 (0.85) | TRPV1 | |
| SCHEMBL6305064 | 0.89 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL5566321 | 0.89 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL6375200 | 0.89 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL6302048 | 0.88 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL6375788 | 0.88 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL5827244 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022182940-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-01 | — | — | WO | claimed |
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | claimed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | claimed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | claimed |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-24 | — | — | US | claimed |
| EP-3363437-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Solutions Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | claimed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | claimed |
| EP-2771320-B1 | CYCLOHEXYLAMINES | ENDO PHARMACEUTICALS INC (US) | 2016-06-22 | — | — | EP | claimed |
| EP-2271329-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | President and Fellows of Harvard College (US) | 2011-01-12 | — | — | EP | claimed |
| US-20100311678-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-12-09 | — | — | US | claimed |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | claimed |
| EP-2101819-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-23 | — | — | EP | claimed |
| WO-2009114139-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-17 | — | — | WO | claimed |
| WO-2009045504-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2008063603-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-05-29 | — | — | WO | claimed |
| US-6476076-B1 | Vanilloid analogues containing resinferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof | PACIFIC CORPORATION (KR) | 2002-11-05 | — | — | US | claimed |
| EP-1154989-A1 | VANILLOID ANALOGUES CONTAINING RESINIFERATOXIN PHARMACOPHORES AS POTENT VANILLOID RECEPTOR AGONISTS AND ANALGESICS, COMPOSITIONS AND USES THEREOF | PACIFIC CORPORATION (KR) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050387-A1 | VANILLOID ANALOGUES CONTAINING RESINIFERATOXIN PHARMACOPHORES AS POTENT VANILLOID RECEPTOR AGONISTS AND ANALGESICS, COMPOSITIONS AND USES THEREOF | PACIFIC CORPORATION (KR) | 2000-08-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311678-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS | PC, PCK2, PDK1 | TRPV1 3963/4885 |
| US-20100099772-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | TRPV1 1/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | TRPV1 2/4885 |
| US-20210186906-A1 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.